Overview
- Pharmexcil reported April–February FY26 exports at $28.29 billion, driven by formulations, biologicals, vaccines and AYUSH products.
- Full-year FY2024–25 exports reached $30.47 billion, a 9.4% increase from the prior year.
- Commerce Secretary Rajesh Agrawal said dollar targets look hard to meet, yet rupee values should rise as the currency weakens.
- Pharmexcil’s Namit Joshi said extra U.S. drug buying worth $1.6 billion in 2025 will weigh on FY26 totals, so results may land near last year until March data are in.
- More than 60% of shipments go to tightly regulated markets, with the U.S. taking 34% and Europe 19%, reflecting compliance with strict quality rules.